Iovance Biotherapeutics, Inc. $IOVA
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-13
ACTIVE TRIALS8
PHASE 3 / 2-31
RECRUITING6
READOUTS ≤12 MONTHS1
READOUT SLIPPED >6 MO40%
Delay Index: of 5 active trials registered more than a year ago, 2 have moved their primary completion (readout) date by more than 6 months since first registration (median +0.0 months). See all sponsors →
Open Iovance Biotherapeutics, Inc. on the live radar map →| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| IOV-4001 NCT05361174 |
P1/2 | Recruiting | Unresectable Melanoma; Metastatic Melanoma | 53 | 2027-09 (+27 mo) |
| Lifileucel NCT07288203 |
P2 | Active, not recruiting | Melanoma (Skin Cancer); Unresectable Melanoma | 24 | 2027-12 |
| Lifileucel plus Pembrolizumab NCT05727904 |
P3 | Recruiting | Metastatic Melanoma; Unresectable Melanoma | 670 | 2028-03-01 |
| Lifileucel NCT06481592 |
P2 | Recruiting | Endometrial Cancer | 60 | 2028-05 |
| LN-145 NCT04614103 |
P2 | Recruiting | Metastatic Non Small Cell Lung Cancer | 170 | 2030-12 (+96 mo) |
| IOV-3001 NCT06940739 |
P1/2 | Recruiting | Unresectable Melanoma; Metastatic Melanoma | 42 | 2032-06 |
| 'SARATOGA' NCT07741877 |
P2 | Recruiting | Sarcoma; Soft Tissue Sarcoma (STS) | 80 | 2033-09-01 |
| IOV-5001 NCT07743723 |
P1/2 | Not yet recruiting | Advanced Solid Tumors; Non-Small Cell Lung Cancer | 106 | 2034-03 |